Gilead Sciences’ (NASDAQ:GILD) fourth-quarter 2022 revenue was $7.4 billion, versus analysts’ expectations of $6.64 billion. Veklury’s revenue in the fourth quarter was $1.00 billion, compared with analysts’ expectations of $533.2 million. Product sales are expected to be $26-26.5 billion in 2023, compared with analysts’ expectations of $25.38 billion. Veklury is expected to generate about $2 billion in revenue in 2023, compared with analysts’ expectations of $1.4 billion.